Everything below concerns GHS-R1a. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-28. Numbers and descriptions here follow the published literature rather than marketing material.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with amidated C-terminus |
| Molecular weight | 711.85 g/mol | Monoisotopic mass |
| Primary receptor | GHS-R1a | Ghrelin receptor, Gq/11 coupled |
| Peptide class | Synthetic pentapeptide | Contains two non-natural residues |
| Reported selectivity | Lower cortisol and prolactin effect | Observed in animal and early human work |
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Shimeji (Japanese: シメジ, 占地 or 湿地) is a group of edible mushrooms native to East Asia, but also found in northern Europe. Hon-shimeji (Lyophyllum shimeji) is a mycorrhizal fungus and difficult to cultivate. Other species are saprotrophs, and buna-shimeji (Hypsizygus tessulatus) is now widely cultivated. Shimeji is rich in umami-tasting compounds such as guanylic acid, glutamic acid, and aspartic acid.
The Oxford crew weighed an average of nearly 2 pounds (0.91 kg) more per rower than their opponents. Oxford's Matthew Pinsent was the heaviest rower while Cambridge's Sinclair Gore was the youngest, aged 19. Cambridge's crew featured three returning Blues in Dirk Bangert, David Gillard and James Behrens, while Oxford saw five former Boat Race rowers return. Overall, half of the rowers were non-British (six nationalities representing Oxford, three representing Cambridge) and the same number were postgraduates. The Cambridge boat club president Behrens claimed: "All our boat are at Cambridge on academic merit. They came for a particular course ... and they also row." In contrast, an editorial in The Times claimed: "The performers are no longer ingenuous native undergraduates but supercharged, international, professional rowing machines." Oxford's Bruce Robertson (men's eight) and Pinsent (coxless pair) were both gold medallists at the Barcelona Olympics. A late change in the Oxford cox saw Samantha Benham replace Gordon Buxton to steer the Dark Blues, becoming the eighth female cox in the history of the race. Oxford's Royle noted that Buxton's form had declined in the run-in to the race, while Benham was "handling the pressure a lot better." Cambridge cox, Martin Haycock, suggested that female coxes were not as accomplished as their male counterparts: "We had one cox who was exceptionally good at giving massages but on the whole ... they're not aggressive or tough enough." Oxford also saw a change to their crew in the week preceding the race.
== Honors and awards == EAS Award for Outstanding Achievements in the Fields of Analytical Chemistry (2023) Martin Medal (2019) Ralph N. Adams Award in Bioanalyical Chemistry (2016) ACS Award in Chromatography (2017) CASSS Award for Outstanding Achievements in Separation Science (2017) Marcel Golay Award for Lifetime Achievement in Capillary Chromatography (2012) Eastern Analytical Symposium Award for Separation Science (2012) McKnight Award for Technical Innovations in Neuroscience (2010) Rackham Distinguished Faculty Achievement Award (2009) American Microchemical Society's Benedetti-Pichler Memorial Award (2001)
Sources: en.wikipedia.org
== Product == The extract is available commercially as Calocurb, an oral dietary supplement for appetite management which was launched in New Zealand in 2018. The capsule has an enteric coating to pass through the stomach and allow delivery to the small intestine.
== Production == Dogtooth was the feature film debut for Boo Productions, an Athens-based advertising company. The Greek Film Center supported the project with about €200,000, and much of the production was done with help from volunteers. Another €50,000 was offered by the production studio. The script was completed in about 2 years, with rehearsals lasting 1+1⁄2 months. The film was shot in about 1 month (in August 2008), and editing took 6 months. Anna Kalaitzidou and Christos Passalis were stage actors who were cast after having worked with Lanthimos earlier. Mary Tsoni was not a professional actress; she was a singer in a punk band. Lanthimos had an open approach to both acting and visual style and felt it would look fake if he involved himself too much in the details. Only when rehearsals started did he begin to develop an idea of the style in which the film should be shot: one where he tried to combine a realistic environment with "really strict framing and a cool, surreal look to go with the narrative".
=== Acute poisoning === Exposure to high level of nitrogen dioxide may lead to inflammation of the mucous membrane and the lower and upper respiratory tracts. The symptoms of acute nitrogen dioxide poisoning is non-specific and have a semblance with ammonia gas poisoning, chlorine gas poisoning, and carbon monoxide poisoning. The symptoms also resembles that of pneumonia or viral infection and other inhalational injuries but common symptoms includes rhinitis wheezing or coughing, conjunctivitis, headache, throat irritation and dyspnea which may progress to nasal fissures, ulcerations, or perforation. The patient is usually ill-appearing and presents with hypoxemia coupled with shallow rapid breathing. Therapy is supportive and includes removal from further nitrogen dioxide exposure. Systemic symptoms include fever and anorexia. Electrocardiography and chest radiography can help in revealing diffuse, bilateral alveolar infiltrates. Chest radiography may be used in diagnosis and the baseline could be established with pulmonary function testing. There is no specific laboratory diagnostic test for acute nitrogen dioxide poisoning but analysis of arterial blood gas level, methemoglobin level, complete blood count, glucose test, lactate threshold measurement and r peripheral blood smear may be helpful in the diagnosis of nitrogen dioxide poisoning. The determination of nitrogen dioxide in urine or tissue does not establish the diagnosis, and there are technical and interpretive problems with these tests.
Pynegabine (developmental code name HN37) is a Kv7.2 and Kv7.3 potassium channel opener which is under development for the treatment of epilepsy in China. The drug is an analogue of flupirtine and retigabine (ezogabine). However, it shows 55-fold greater potency in activating Kv7.2 channels and 127-fold greater potency in activating Kv7.3 channels compared to retigabine in vitro. In addition, it shows improved chemical or metabolic stability compared to retigabine and in relation to this may have reduced toxicity in comparison. The drug is under development by the Shanghai Institute of Materia Medica and Hainan Haiyao. As of 2026, it is in phase 2 clinical trials for epilepsy.
Sources: en.wikipedia.org
It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.
Both act at the same G protein-coupled receptor, but ipamorelin is a short synthetic peptide with modified residues rather than the natural 28-amino-acid hormone. Reports describe weaker effects on appetite and on cortisol or prolactin release than those seen with ghrelin. Its resistance to enzymatic breakdown also differs from that of the natural ligand.
Receptor binding and downstream calcium signaling are well characterized in cell-based systems. Effects measured in whole organisms are less consistent across studies and species. The extent to which selective receptor behavior drives the observed hormonal profile is still debated.
Typical guidance is -20 °C in a sealed container with desiccant and protection from light. The powder tolerates handling better than a solution, but repeated warming and cooling is still avoided.